microdosing glp-1 for menopause During Menopause: Is it Right You? Microdosing GLP-1: A Next-Generation Approach

Future research investigating if glycogen synthesis and storage is increased in these tissues after the pharmacologic use of GLP-1 agonists may be useful in determining if these effects are clinically significant

There are several types of GLP medications that engage different types of glucagon receptors, giving them different effects in different people: Single receptor agonists (GLP-1 only): Ozempic, Wegovy, Saxenda Dual receptor agonists (GLP-1 + GIP): Mounjaro, Zepbound Triple receptor agonists (GLP-1 + GIP + glucagon): in development early studies show even greater metabolic effects These medications are changing how we are able to ameliorate obesity, food addiction, insulin resistance, and cardiometabolic risks

El principio activo tanto de Ozempic como de Wegovy es el mismo, pero las dosis son diferentes

Ayuda a controlar el azcar en sangre mejorando la secrecin de insulina

When you deliberately fall back into old habits of overeating, this is taking a step backwards, and could even set you up for failure over the long term

Pancreatitis and Medullary Thyroid Carcinoma (MTC): while existing evidence has not established a definitive causal link, screening for and avoiding use in patients with a history of pancreatitis, MTC, or a family history of Multiple Endocrine Neoplasia type 2 (MEN2) remains a mandatory precautionary measure (144148)